Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 56

1.

Sensitivity of osteosarcoma cells to HDAC inhibitor AR-42 mediated apoptosis.

Murahari S, Jalkanen AL, Kulp SK, Chen CS, Modiano JF, London CA, Kisseberth WC.

BMC Cancer. 2017 Jan 21;17(1):67. doi: 10.1186/s12885-017-3046-6.

2.

Suppression of Tumor Growth and Muscle Wasting in a Transgenic Mouse Model of Pancreatic Cancer by the Novel Histone Deacetylase Inhibitor AR-42.

Henderson SE, Ding LY, Mo X, Bekaii-Saab T, Kulp SK, Chen CS, Huang PH.

Neoplasia. 2016 Dec;18(12):765-774. doi: 10.1016/j.neo.2016.10.003. Epub 2016 Nov 25.

3.

Preclinical Pharmacokinetics Study of R- and S-Enantiomers of the Histone Deacetylase Inhibitor, AR-42 (NSC 731438), in Rodents.

Cheng H, Xie Z, Jones WP, Wei XT, Liu Z, Wang D, Kulp SK, Wang J, Coss CC, Chen CS, Marcucci G, Garzon R, Covey JM, Phelps MA, Chan KK.

AAPS J. 2016 May;18(3):737-45. doi: 10.1208/s12248-016-9876-3. Epub 2016 Mar 4.

4.

Integrin-linked kinase as a novel molecular switch of the IL-6-NF-κB signaling loop in breast cancer.

Hsu EC, Kulp SK, Huang HL, Tu HJ, Chao MW, Tseng YC, Yang MC, Salunke SB, Sullivan NJ, Chen WC, Zhang J, Teng CM, Fu WM, Sun D, Wicha MS, Shapiro CL, Chen CS.

Carcinogenesis. 2016 Apr;37(4):430-442. doi: 10.1093/carcin/bgw020. Epub 2016 Feb 19.

5.

Non-epigenetic function of HDAC8 in regulating breast cancer stem cells by maintaining Notch1 protein stability.

Chao MW, Chu PC, Chuang HC, Shen FH, Chou CC, Hsu EC, Himmel LE, Huang HL, Tu HJ, Kulp SK, Teng CM, Chen CS.

Oncotarget. 2016 Jan 12;7(2):1796-807. doi: 10.18632/oncotarget.6427.

6.

Development of Potent Adenosine Monophosphate Activated Protein Kinase (AMPK) Activators.

Dokla EM, Fang CS, Lai PT, Kulp SK, Serya RA, Ismail NS, Abouzid KA, Chen CS.

ChemMedChem. 2015 Nov;10(11):1915-23. doi: 10.1002/cmdc.201500371. Epub 2015 Sep 9.

7.

Function of Integrin-Linked Kinase in Modulating the Stemness of IL-6-Abundant Breast Cancer Cells by Regulating γ-Secretase-Mediated Notch1 Activation in Caveolae.

Hsu EC, Kulp SK, Huang HL, Tu HJ, Salunke SB, Sullivan NJ, Sun D, Wicha MS, Shapiro CL, Chen CS.

Neoplasia. 2015 Jun;17(6):497-508. doi: 10.1016/j.neo.2015.06.001.

9.

Exploitation of the ability of γ-tocopherol to facilitate membrane co-localization of Akt and PHLPP1 to develop PHLPP1-targeted Akt inhibitors.

Yan R, Chuang HC, Kapuriya N, Chou CC, Lai PT, Chang HW, Yang CN, Kulp SK, Chen CS.

J Med Chem. 2015 Mar 12;58(5):2290-8. doi: 10.1021/jm501751b. Epub 2015 Feb 27.

10.

Sensitization of intracellular Salmonella enterica serovar Typhimurium to aminoglycosides in vitro and in vivo by a host-targeted antimicrobial agent.

Lo JH, Kulp SK, Chen CS, Chiu HC.

Antimicrob Agents Chemother. 2014 Dec;58(12):7375-82. doi: 10.1128/AAC.03778-14. Epub 2014 Sep 29.

11.

AMPK reverses the mesenchymal phenotype of cancer cells by targeting the Akt-MDM2-Foxo3a signaling axis.

Chou CC, Lee KH, Lai IL, Wang D, Mo X, Kulp SK, Shapiro CL, Chen CS.

Cancer Res. 2014 Sep 1;74(17):4783-95. doi: 10.1158/0008-5472.CAN-14-0135. Epub 2014 Jul 3.

12.

Targeting the Warburg effect with a novel glucose transporter inhibitor to overcome gemcitabine resistance in pancreatic cancer cells.

Lai IL, Chou CC, Lai PT, Fang CS, Shirley LA, Yan R, Mo X, Bloomston M, Kulp SK, Bekaii-Saab T, Chen CS.

Carcinogenesis. 2014 Oct;35(10):2203-13. doi: 10.1093/carcin/bgu124. Epub 2014 May 30.

13.

Extra-prostatic transgene-associated neoplastic lesions in transgenic adenocarcinoma of the mouse prostate (TRAMP) mice.

Berman-Booty LD, Thomas-Ahner JM, Bolon B, Oglesbee MJ, Clinton SK, Kulp SK, Chen CS, La Perle KM.

Toxicol Pathol. 2015 Feb;43(2):186-97. doi: 10.1177/0192623314531351. Epub 2014 Apr 17.

14.

Prospects on strategies for therapeutically targeting oncogenic regulatory factors by small-molecule agents.

Chou CC, Salunke SB, Kulp SK, Chen CS.

J Cell Biochem. 2014 Apr;115(4):611-24. doi: 10.1002/jcb.24704. Review.

15.
16.

AMPK as a potential anticancer target - friend or foe?

Chuang HC, Chou CC, Kulp SK, Chen CS.

Curr Pharm Des. 2014;20(15):2607-18. Review.

17.

Functional Role of mTORC2 versus Integrin-Linked Kinase in Mediating Ser473-Akt Phosphorylation in PTEN-Negative Prostate and Breast Cancer Cell Lines.

Lee SL, Chou CC, Chuang HC, Hsu EC, Chiu PC, Kulp SK, Byrd JC, Chen CS.

PLoS One. 2013 Jun 19;8(6):e67149. doi: 10.1371/journal.pone.0067149. Print 2013.

18.

Toward personalized therapy in AML: in vivo benefit of targeting aberrant epigenetics in MLL-PTD-associated AML.

Bernot KM, Siebenaler RF, Whitman SP, Zorko NA, Marcucci GG, Santhanam R, Ahmed EH, Ngangana M, McConnell KK, Nemer JS, Brook DL, Kulp SK, Chen CS, Frankhouser D, Yan P, Bundschuh R, Zhang X, Dorrance AM, Dickerson KE, Jarjoura D, Blum W, Marcucci G, Caligiuri MA.

Leukemia. 2013 Dec;27(12):2379-82. doi: 10.1038/leu.2013.147. Epub 2013 May 10. No abstract available.

19.

Vitamin E facilitates the inactivation of the kinase Akt by the phosphatase PHLPP1.

Huang PH, Chuang HC, Chou CC, Wang H, Lee SL, Yang HC, Chiu HC, Kapuriya N, Wang D, Kulp SK, Chen CS.

Sci Signal. 2013 Mar 19;6(267):ra19. doi: 10.1126/scisignal.2003816.

20.

Suppression of prostate epithelial proliferation and intraprostatic progrowth signaling in transgenic mice by a new energy restriction-mimetic agent.

Berman-Booty LD, Chu PC, Thomas-Ahner JM, Bolon B, Wang D, Yang T, Clinton SK, Kulp SK, Chen CS.

Cancer Prev Res (Phila). 2013 Mar;6(3):232-41. doi: 10.1158/1940-6207.CAPR-12-0057. Epub 2012 Dec 28.

Supplemental Content

Loading ...
Support Center